Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance

The American Review of Respiratory Disease
F ManaloM D Iseman

Abstract

A community-based tuberculosis case-finding and short-course chemotherapy program was conducted in a suburb of Manila and featured 1 month of daily isoniazid (INH), rifampin (RIF), ethambutol (EMB), and pyrazinamide (PZA) followed by 7 months of twice-weekly, high dose, directly observed INH + EMB + PZA. Church-affiliated lay workers obtained 1,990 sputum specimens from subjects who complained of chronic cough or wasting symptoms; 207 of the specimens were positive on Ziehl-Neelsen smears. On culture, 176 yielded a significant growth of M. tuberculosis. Of these 176 patients, 144 were selected to enter the study; 10 were lost because of withdrawal or death and four (2.7%) because of drug toxicity. This left 130 patients who were followed long-term. Remarkably, 80% (104) were initially shedding drug-resistant organisms; 26% (34) were resistant to one drug, 30% (40) were resistant to two drugs, and 24% (30) were resistant to three or more drugs. Responses to therapy corresponded closely to the extent of drug resistance: 80% (48 of 60) of patients with drug-susceptible or single resistance had a favorable outcome; 43% (28 of 65) were resistant to two or three drugs, and 0% (0 of 5) of those were resistant to four or more drugs. No...Continue Reading

Citations

May 1, 1992·Research in Microbiology·J D van EmbdenP W Hermans
Sep 24, 2008·Seminars in Respiratory and Critical Care Medicine·Carole D MitnickSonya S Shin
Mar 1, 1997·The Pediatric Infectious Disease Journal·S W LindquistJ R Starke
May 1, 1993·The American Review of Respiratory Disease·E Sumartojo
Dec 1, 1993·The American Review of Respiratory Disease·N KennedyS H Gillespie
Feb 18, 1995·Lancet·J M Fitzgerald
Apr 25, 2000·Lancet·J VolminkP Garner
Dec 1, 1995·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·G CarpelsF Portaels
Dec 1, 1992·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·P Sukrakanchana-TrikhamH L Rieder
Jun 1, 1993·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·M DattaR Prabhakar
Oct 1, 1994·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·H L Rieder
Aug 1, 1994·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·P R Gangadharam
Apr 20, 2005·Clinics in Chest Medicine·Thomas R Frieden, Sonal S Munsiff
Aug 21, 2002·Expert Opinion on Pharmacotherapy·James DeMaio, Dian Sharma
Nov 1, 2001·The Cochrane Database of Systematic Reviews·H C Mwandumba, S B Squire
Jan 1, 1996·Scandinavian Journal of Infectious Diseases·M E EllisS M Hussein Qadri
May 5, 2000·The Cochrane Database of Systematic Reviews·H C Mwandumba, S B Squire
Sep 20, 1993·The Medical Journal of Australia·V L Krause, W J Britton
Oct 19, 1999·Journal of Clinical Microbiology·V O ThomsenH J Burkardt
Jun 3, 2006·Pediatrics·Peter C DrobacMercedes C Becerra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Related Papers

BMJ : British Medical Journal
P Godfrey-FaussettR Msiska
Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
L X Zhang, G Q Kan
Computerized Medical Imaging and Graphics : the Official Journal of the Computerized Medical Imaging Society
T B BuxiS P Byotra
The Journal of Infectious Diseases
G RodierC S Omar
© 2021 Meta ULC. All rights reserved